Table 4.
Comparison of caffeine pharmacokinetics after administration of 100 mg of caffeine between different formulations
|
Cmax
(ng ml–1) |
Tmax
(h) |
AUC (ng ml–1 × h) |
V/F/kg (l kg–1) |
CL/F/kg (l h–1 kg–1) |
t½ (h) |
Study | |
|---|---|---|---|---|---|---|---|
| Capsule | 1840 ± 700 | 1.56 ± 0.76 | 14 700 ± 7260 | 0.77 ± 0.38 | 0.116 ± 0.070 | 4.3 | Kamimori 7 |
| Gum | 1200 ± 510 | 1.25 ± 0.77 | 10 900 ± 7000 | 1.17 ± 0.17 | 0.171 ± 0.100 | 4.6 | Kamimori 7 |
| ED | 1939 ± 341 | 0.88 ± 0.57 | 17 569 ± 6869 | 0.71 ± 0.09 | 0.089 ± 0.035 | 6.0 | Laizure |
| AeroShot | 1790 ± 686 | 1.34 ± 0.83 | 15 579 ± 8387 | 0.87 ± 0.43 | 0.135 ± 0.128 | 5.3 | Laizure |
| ED | 1963* | 1.17 ± 0.73 | 21948* | 0.71 ± 0.41 | 0.090 ± 0.048 | 6.7 | White 15 |
| Coffee (hot) | 2338* | 0.98 ± 0.45 | 24083* | 0.62 ± 0.13 | 0.072 ± 0.036 | 6.8 | White 15 |
*
Caffeine dose 160 mg. Cmax and AUC normalized to 100 mg caffeine dose.
Cmax, peak caffeine plasma concentration; AUC, area under the concentration–time curve; Tmax, time of peak caffeine plasma concentration; CL/F, clearance/bioavailability; V/F, volume of distribution/bioavailability